GlassScriptPhysician profile
Debra R Bailey
NPI 1457331555
$939.87
in general payments reported to CMS, 2019-2025
17 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $69.05 · 2021: $22.98 · 2022: $30.58 · 2023: $111 · 2024: $415 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $244.60 | 2019-2024 | Bexsero |
| Shield Therapeutics INC | $175.58 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $98.38 | 2024-2025 | Purified Cortrophin Gel |
| Pfizer INC. | $74.96 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $67.58 | 2020-2024 | Vaxelis, Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.42 | 2024 | Xifaxan |
| Daiichi Sankyo INC. | $43.99 | 2024 | Injectafer |
| Sobi, INC | $34.25 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.07 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $20.25 | 2025 | |
| Gynesonics, INC. | $18.71 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Ultragenyx Pharmaceutical INC. | $18.31 | 2022 | |
| Tris Pharma INC | $18.27 | 2025 | Dyanavel Xr |
| Abbott Laboratories | $15.77 | 2024 | Freestyle Libre 3 |
| Sage Therapeutics, LLC | $14.47 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13.64 | 2025 | |
| Exeltis, USA INC. | $13.62 | 2023 | Nuvessa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.